Related references
Note: Only part of the references are listed.Therapeutic Potential of Afatinib inNRG1Fusion-Driven Solid Tumors: A Case Series
Jacques Cadranel et al.
ONCOLOGIST (2021)
Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
Adriana Estrada-Bernal et al.
CLINICAL CANCER RESEARCH (2021)
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
Alexander Drilon et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
NRG1 fusions in breast cancer
Karen D. Howarth et al.
BREAST CANCER RESEARCH (2021)
A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.
Alison M. Schram et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Characterization of NRG1 gene fusion events in solid tumors.
Sushma Jonna et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions
S. V. Liu et al.
ANNALS OF ONCOLOGY (2020)
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Ryma Benayed et al.
CLINICAL CANCER RESEARCH (2019)
Detection of NRG1 Gene Fusions in Solid Tumors
Sushma Jonna et al.
CLINICAL CANCER RESEARCH (2019)
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma
Martin R. Jones et al.
CLINICAL CANCER RESEARCH (2019)
Wake Up and Smell the Fusions: Single-Modality Molecular Testing Misses Drivers
Kurtis D. Davies et al.
CLINICAL CANCER RESEARCH (2019)
Detection of NRG1 Fusions in Solid Tumors: Rare Gold?
Anastasios Dimou et al.
CLINICAL CANCER RESEARCH (2019)
Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Alison M. Schram et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Resistance Mechanisms to Targeted Therapies in ROS1(+) and ALK(+) Non-small Cell Lung Cancer
Caroline E. McCoach et al.
CLINICAL CANCER RESEARCH (2018)
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
Alexander Drilon et al.
CANCER DISCOVERY (2018)
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Christoph Heining et al.
CANCER DISCOVERY (2018)
Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression
Domenico Trombetta et al.
Oncotarget (2018)
EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion
Hye Sook Kim et al.
LUNG CANCER (2018)
A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib
Parneet K. Cheema et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions
Nathan D. Gay et al.
Journal of Thoracic Oncology (2017)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer
M. R. Jones et al.
ANNALS OF ONCOLOGY (2017)
Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung
Dong Hoon Shin et al.
ONCOTARGET (2016)
Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung
Hyo Sup Shim et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
Takashi Nakaoku et al.
CLINICAL CANCER RESEARCH (2014)
CD74-NRG1 Fusions in Lung Adenocarcinoma
Lynnette Fernandez-Cuesta et al.
CANCER DISCOVERY (2014)
Neuregulins: functions, forms, and signaling strategies
DL Falls
EXPERIMENTAL CELL RESEARCH (2003)
Share Paper
